Autologous T-cell vaccination for multiple sclerosis: A perspective on progress

BioDrugs

Volumn 22, Issue 4, 2008, Pages 265-273

  Vandenbark, Arthur A ^a,b   Abulafia Lapid, Rivka ^b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Immunomodulators, therapeutic use; Multiple sclerosis, treatment; Vaccines, therapeutic use

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID DERIVATIVE; FINGOLIMOD; GLATIRAMER; INTERFERON; MITOXANTRONE; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; PLACEBO; PROTEOLIPID PROTEIN; T CELL VACCINE; VACCINE;

BYSTANDER EFFECT; CELL SELECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ENCEPHALITIS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INJECTION SITE REACTION; IRRADIATION; LONGITUDINAL STUDY; MULTIFOCAL LEUKOENCEPHALITIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SKIN REDNESS; TARGET CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; T-LYMPHOCYTES; VACCINATION;

EID: 47049096574     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822040-00006     Document Type: Review

References (60)

1. Raine CS, Scheinberg LC. On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 1988; 20: 189-94
2. Charcot J-M. Histologie de la sclerose en plaques. Gazette des Hopitaux, Paris 1868; 41: 554-5
3. Trapp BD, Peterson J, Ransohoff RM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
4. Steinman L. Multiple sclerosis: a two stage disease. Nat Immunol 2001; 2: 762-5
5. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80 (5): 695-705
6. Hemmer BM, Vergelli B, Gran N, et al. Cutting edge: predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 1998; 160: 3631-6
7. Vandenbark AA. TCR peptide vaccination in multiple sclerosis: boosting a deficient regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets Inflamm Allergy 2005; 4: 85-94
8. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17
9. Wang C, Gold BG, Kaler LJ, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006; 98: 1817-27
10. Hellings N, Raus J, Stinissen P. Insights into the immunopathogenesis of multiple sclerosis. Immunol Res 2002; 25: 27-51
11. Olsson T, Wang WZ, Hojeberg B, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86: 981-5
12. Sun JB, Olsson T, Wang WZ, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21: 1461-8
13. Chou YK, Bourdette DN, Offner H, et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105-14
14. Ota K, Matsui M, Milford EL, et al. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-5
15. Trotter JL, Pelfrey CM, Trotter AL, et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 1998; 84: 172-8
16. van Noort JM, vanSechel AC, Bajramovic JJ, et al. The small heat-shock protein a-B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995; 375: 798-801
17. deRosbo NK, Milo R, Lees MB, et al. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92: 2602-8
18. Bieganowska KD, Ausubel LJ, Modabber Y, et al. Direct ex vivo analysis of activated fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997; 185: 1585-94
19. Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973-84
20. Wilson DB, Golding AB, Smith RA, et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis: I, analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol 1997; 76: 15-28
21. Allegretta M, Nicklas JA, Sriram S, et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247: 718-21
22. Lodge PA, Johnson C, Sriram S. Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients. Neurology 1996; 46: 1410-5
23. Trotter JL, Damico CA, Cross AH, et al. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 1997; 75: 95-103
24. Vandenbark AA, Bourdette DN, Whitham R, et al. Episodic changes in T cell frequencies to myelin basic protein in patients with multiple sclerosis. Neurology 1993; 43: 2416-7
25. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T cell receptor peptides: results of a double-blind pilot trial. Nature Med 1996; 2: 1109-15
26. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-4
27. Zhang J, Medaer R, Stinissen P, et al. MHC restricted clonotypic depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993; 261: 1451-4
28. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med 2000; 6: 1167-75
29. Hemmer B, Stefanova I, Vergelli M, et al. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998; 160: 5807-14
30. Ho HZ, Tiwari JL, Haile RW, et al. HLA-linked and unlinked determinants of multiple sclerosis. Immunogenetics 1982; 15: 509-17
31. Francis DA, Batchelor JR, McDonald WI, et al. Multiple sclerosis and HLA-DQw1. Lancet 1986; 1: 211
32. Kellar-Wood HF, Wood NW, Holmans P, et al. Multiple sclerosis and the HLA-D region: linkage and association studies. J Neuroimmunol 1995; 58: 183-90
33. Hauser SL. T-cell receptor genes: germline polymorphisms and genetic susceptibility to demyelinating diseases. Ann N Y Acad Sci 1995; 756: 233-40
34. Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994; 179: 279-90
35. Noseworthy JH, Gold R, Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999; 12: 279-93
36. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
37. Rudick RA, Stuart WH, Calabrese PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23
38. Bar-Or A. Effects of long-term fingolimod therapy on circulating mononuclear cell populations in multiple sclerosis [abstract]. Clin Immunol 2007; 123 Suppl.: 563
39. Muir M, Lovett-Racke AE, Racke MK. Novel therapeutic strategies targeting the pathogenic T cells in multiple sclerosis. Exp Rev Clin Immunol 2005; 1: 345-55
40. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalo-myelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981; 292: 60-1
41. Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol 2006; 64: 205-10
42. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541-4
43. Howell MD, Winters ST, Olee T, et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989; 246: 668-70
44. Zang YCQ, Hong J, Rivera VM, et al. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 2000; 164: 4011-7
45. Hong J, Zang YCQ, Nie H, et al. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5024-9
46. Hellings N, Raus J, Stinissen P. T-cell-based immunotherapy in multiple sclerosis: induction of regulatory immune networks by T-cell vaccination. Expert Rev Clin Immunol 2006; 2: 705-16
47. van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003; 131: 155-68
48. Hafler DA, Cohen I, Benjamin DS, et al. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992; 62: 307-13
49. Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein autoreactive T cells by T cell vaccination: pilot trial in multiple sclerosis. Lancet 1995; 346: 807-8
50. Hermans G, Denzer U, Lohse A, et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmunity 1999; 13: 233-46
51. Zhang JZ, Rivera VM, Tejada-Simon MV, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002; 249: 212-8
52. Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000; 107: 130-9
53. Achiron A, Lavie G, Kishner I, et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponder patients. Clin Immunol 2004; 113: 155-60
54. Stinissen P, Zhang J, Medaer R, et al. Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 1996; 45: 500-11
55. Hermans G, Medaer R, Raus J, et al. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000; 102: 79-84
56. Stinissen P, Hermans G, Hellings N, et al. Functional characterization of CD8 anticlonotypic T cells from MS patients treated with T cell vaccination [abstract]. J Neuroimmunol 1998; 90: A564
57. Zang YCQ, Hong J, Tejada-Simon MV, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000; 30: 908-13
58. Buenafe AC, Tsaknaridis LJ, Spencer L, et al. Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 2004; 76: 129-40
59. Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent T cell receptor peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2007; 123: 66-78
60. Hong J, Zang Y, Tejada-Simon MV, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol 2000; 165: 6858-64